SH3 domain binding protein 4Genealiases: BOG25 · TTP
Q-omics provides the consensus-scored SH3BP4 profile across patient tissues and cancer cell-line models. SH3BP4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SH3BP4 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, SH3BP4 protein abundance shows 25,293 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, KIRC, and HNSC as cancer lineages where SH3BP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3BP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3BP4 survival associations across molecular data types. SH3BP4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3BP4 RNA expression–survival associations across cancer types. High SH3BP4 expression shows unfavorable associations in ACC, KIRP, SKCM and LUSC, but favorable associations in KIRC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SH3BP4 RNA expression.
This table summarizes SH3BP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SH3BP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3BP4 shows lower tumor expression in KIRC, KIRP and THCA and higher tumor expression in COAD, HNSC and STAD. The KIRC box plot shows higher SH3BP4 RNA expression in normal versus tumor tissue (log2 FC = −1.181, t-test p < 0.001).
This table shows molecular features associated with SH3BP4 in patient tissues and cancer cell lines. In patient samples, SH3BP4 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SH3BP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
